Skip to main navigation Investors Careers Header Navigation Therapeutic Areas News Resources About Us Contact Us Stock Information Financial Information Corporate Governance Shareholder Services Press Release Home > Investors > News & Events > Press Releases > LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference RSS Feeds Email Alerts Contact Us LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference Nov 23, 2021 Download PDF LONDON--(BUSINESS WIRE)--Nov. 23, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald, Chief Executive Officer, will participate in discussions at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021. Meetings can be requested exclusively through Piper Sandler. The pre-recorded discussion with LivaNova and Piper Sandler is available via the Investors section of the LivaNova website at www.livanova.com and will remain accessible for 90 days. About LivaNova LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com. Safe Harbor Statement This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005008/en/ LivaNova Investor Relations and Media Contacts +1 281-895-2382 Lindsey Little Senior Director, Investor Relations InvestorRelations@livanova.com Deanna Wilke VP, Corporate Communications Corporate.Communications@livanova.com Source: LivaNova PLC Therapeutic Areas Advanced Circulatory Support Cardiopulmonary Difficult-to-Treat Depression Drug-Resistant Epilepsy Heart Failure Heart Valves Obstructive Sleep Apnea Resources Contact Us Customer Service Research Support Request Donations & Grants About Us Leadership Ethics & Compliance Modern Slavery Statement Conflict Minerals Terms of Use Privacy Statement Privacy Notice Patents Cookie Policy © 2021 LivaNova PLC LivaNova PLC - Registered in England and Wales - Registered No. 09451374 - 20 Eastbourne Terrace, London, W2 6LG, United Kingdom